Giménez-Orenga 2025 — Blood-parameter panel differentiates post-COVID from FM/ME-CFS

One-paragraph summary

Same Oltra-group lineage as the 2023 HERV classifier and the 2025 Martín-Martínez case report. The paper tackles the differential-diagnosis problem: post-COVID condition, ME/CFS, and FM share substantial symptom overlap, and over half of post-SARS-CoV-2 patients fulfill ME/CFS and/or FM clinical criteria after a few months. The authors measured a comprehensive blood panel: anti-SARS-CoV-2 spike + nucleocapsid IgM/IgG/IgA/IgE; cytokines (IL-6, IL-8, IL-10, IFNγ, TNFα); NfL (neural damage marker); peripheral blood cell markers — alongside HERV-W ENV protein detection. Some panel components achieved 100% sensitivity, 71.9% specificity for differentiating post-COVID condition from FM/ME-CFS/HC. Importantly: HERV-W ENV was detected in pre-pandemic FM/ME-CFS samples too, replicating the Oltra 2023 finding and establishing that the HERV reactivation mechanism is a general post-viral phenomenon, not COVID-specific. The clinical implication is direct: a multi-marker blood panel can route patients into specific cells of the H1×H2 subtype matrix and into the post-COVID/non-post-COVID cell, enabling subtype-stratified treatment.

Claims as triples

• post_covid_differentiation_panel — predicts → post_covid_syndrome [evidence: 100% sens / 71.9% spec; confidence: emerging]
• HERV_W_ENV — bridges → post_covid_syndrome [evidence: prepandemic detection in FM/ME-CFS; confidence: emerging]
• HERV_reactivation — present_in → fm_autoimmune [strengthened: HERV-W ENV detection in pre-pandemic FM cohort; confidence: emerging]
• viral_infection — causes → HERV_reactivation [evidence: post-COVID highest detection rate; confidence: emerging]
• NfL — predicts → neuroinflammation_glial [evidence: established neural-damage marker; confidence: established]

Methods note

Cross-sectional case-control. Cohorts: post-COVID condition, ME/CFS, FM, co-diagnosed, healthy controls. Blood collected and panel measured: ELISA for spike/nucleocapsid antibody isotypes; multiplex cytokine panel; NfL by Simoa; HERV-W ENV by ELISA/Western. Multi-component classifier built and validated. Authors: international consortium led by Oltra (Universidad CEU Cardenal Herrera, Spain) + Perron (the GeNeuro/HERV-W research lineage).

Limitations

• Cross-sectional design; cannot establish temporal sequence (e.g., NfL elevation could be downstream of disease rather than upstream cause).
• Sample sizes per cohort moderate; the 100% sensitivity figure is a small-cohort phenomenon and may not survive replication at scale.
• The 71.9% specificity means ~28% of FM/ME-CFS/HC are false-positive for "post-COVID" — clinically meaningful misclassification rate.
• Different cytokines/markers presumably contribute differently to the classifier; interpreting which markers are load-bearing requires the full text.
• Did not stratify FM cohort by anti-SGC IgG status or by the H1×H2 matrix; the panel doesn't yet route to specific FM subtypes.

Open questions raised

• Which subset of the panel (anti-spike Ab? cytokines? NfL? HERV-W ENV?) carries the differentiation signal? Component-wise importance analysis would refine the panel for clinical deployment.
• Does the panel distinguish post-COVID FM from non-post-COVID FM at the cell level of the H1×H2 matrix? (I.e., is post-COVID FM a fifth cell, or does it overlay onto existing cells?)
• Is NfL elevation FM-specific or post-viral-condition-specific? Tests whether the post-viral conditions have detectable axonal injury that idiopathic FM doesn't.

Triangulation notes

• Replicates Oltra 2023 finding that HERV-W ENV is present in pre-pandemic FM/ME-CFS. The mechanism is robust across two papers from the same research group, strengthening the HERV-reactivation upstream hypothesis.
• Validates a candidate biomarker panel for the biomarker-mapping cohort. The Giménez-Orenga panel is a candidate component to add alongside the seven dimensions already proposed in causal-chain-hypotheses.md §6.2 — measuring this would specifically differentiate post-COVID FM from other FM at intake.
• NfL adds a neural-damage axis that's distinct from the autoimmune axis (anti-SGC IgG) and the inflammatory axis (TSPO-PET). If post-COVID FM shows NfL elevation but idiopathic FM doesn't, this would suggest post-COVID FM has a neurodegenerative component that idiopathic FM lacks — a substantively different cure-path implication (post-COVID FM might benefit from neuroprotective therapy that idiopathic FM doesn't need).
• The Oltra group is producing a coherent research lineage: 2023 HERV classifier → 2025 Martín-Martínez HERV-MS-rituximab case → 2025 Giménez-Orenga differentiation panel. The project should monitor this group's output systematically.

Bridges

• B7 (HERV ↔ FM autoimmune subtype) strengthened by replication of HERV-W ENV detection in pre-pandemic FM.
• B6 (post-infectious nociplastic conditions ↔ FM) operationalized — the differentiation panel is the candidate stratification tool for the post-infectious cluster framework.
• New possible bridge: NfL ↔ post-viral FM specifically — would distinguish post-COVID FM as having a neurodegenerative component absent in idiopathic FM.